59 completed, 14 terminated, 12 unknown, 4 recruiting. 98 Phase 2, 25 Phase 1, 15 Phase 3.
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-11-01 | 2026-11-05 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-04-15 | 2026-08-06 |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) Tiespectus, Aflibercept - Macular Degeneration, Age-Related Macular Degeneration | Phase 2 / Phase 3 | Recruiting | EyeBiotech Ltd. | 960 | 2026-03-27 | 2026-10-02 |
| Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma 82-Rb injection - Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2026-01-01 | 2026-01-16 |
| Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. Intrastromal anti-VEGF injection and topical antiviral eye drops, Conventional antiviral topical ocular drops. - Herpes Simplex Keratitis, Corneal Neovascularization | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2025-10-01 | 2026-01-09 |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration NG101 AAV gene therapy - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Elisigen, Inc. | 20 | 2023-09-08 | 2026-09-10 |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] ADVM-022 - Neovascular Age-related Macular Degeneration | Phase 2 | Active not recruiting | Adverum Biotechnologies, Inc. | 69 | 2022-08-23 | 2026-10-27 |
| Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin bevacizumab with oral curcumin, bevacizumab with oral placebo - Diabetic Macular Edema, Macular Edema | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 52 | 2021-10-10 | 2024-09-19 |
| The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization KDR2-2 suspension eye drops - Corneal Neovascularization | Phase 1 / Phase 2 | Unknown | Zhongshan Ophthalmic Center, Sun Yat-sen University | 60 | 2021-08-10 | 2021-08-18 |
| Corneal Crosslinking for Treatment of Corneal Neovascularization 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1% - Corneal Neovascularization | Phase 2 / Phase 3 | Recruiting | Price Vision Group | 138 | 2021-05-03 | 2026-09-17 |
| Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD ABBV-RGX-314, Ranibizumab (LUCENTIS®) - AMD, nAMD | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 671 | 2020-12-29 | 2026-04-28 |
| A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration RBM-007 Injectable Solution, Aflibercept, Sham - Exudative Age-related Macular Degeneration | Phase 2 | Completed | Ribomic USA Inc | 94 | 2019-12-02 | 2023-06-08 |
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Zimura, Eylea - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Withdrawn | Ophthotech Corporation | 2018-11-01 | 2024-02-21 | |
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
| Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) ICON-1, aflibercept - Choroidal Neovascularization, Wet Macular Degeneration | Phase 2 | Terminated | Iconic Therapeutics, Inc. | 15 | 2018-03-26 | 2021-04-13 |
| Ziv-aflibercept Efficacy in Better Regulating AMD Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab - Wet Macular Degeneration, Wet Age-related Macular Degeneration | Phase 2 | Completed | Kapil Kapoor | 62 | 2017-07-07 | 2020-10-06 |
| Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Aflibercept - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Rabin Medical Center | 6 | 2017-03-02 | 2019-09-16 |
| Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration Faricimab, Ranibizumab, Sham Procedure - Neovascularization, Choroidal, Macular Degeneration, Age-Related | Phase 2 | Completed | Hoffmann-La Roche | 76 | 2017-01-27 | 2021-01-05 |
| Conbercept in Choroidal Neovascularization Secondary to Uveitis Conbercept, sham - Choroidal Neovascularization, Uveitis | Phase 2 | Unknown | Chongqing Medical University | 40 | 2016-11-01 | 2016-10-17 |
Showing 20 of 98. Sign in to see all of them.
Choroidal Neovascularization (57) · Macular Degeneration (46) · Neovascularization, Pathologic (16) · Corneal Neovascularization (12) · Polypoidal Choroidal Vasculopathy (9) · Retinal Neovascularization (9) · Wet Macular Degeneration (8) · Diabetic Retinopathy (5) · Eye Diseases (4) · Macular Edema (4) · Retinal Degeneration (4) · Retinal Diseases (4) · Angioid Streaks (3) · Myopia, Degenerative (3) · Pseudoxanthoma Elasticum (3)
Pathologic Processes (98) · Pathological Conditions, Signs and Symptoms (98) · Eye Diseases (85) · Neovascularization, Pathologic (82) · Choroid Diseases (64) · Uveal Diseases (64) · Retinal Diseases (57) · Retinal Degeneration (47) · Cardiovascular Diseases (11) · Corneal Diseases (11) · Vascular Diseases (10) · Choroidal Neovascularization (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Diabetes Complications (6)
Ranibizumab (32) · Bevacizumab (14) · aflibercept (14) · Verteporfin (7) · salicylhydroxamic acid (5) · Dexamethasone (3) · Sirolimus (3) · Sodium Chloride (3) · fosbretabulin (3) · pazopanib (3) · Carboxymethylcellulose Sodium (2) · faricimab (2) · 4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol (1) · Adalimumab (1) · Celecoxib (1)
Allergan (4) · Reza Dana, MD (4) · Ophthotech Corporation (3) · Asociación para Evitar la Ceguera en México (2) · Chengdu Kanghong Biotech Co., Ltd. (2) · EyeBiotech Ltd. (2) · GlaxoSmithKline (2) · Hoffmann-La Roche (2) · Hospices Civils de Lyon (2) · Iconic Therapeutics, Inc. (2) · Johns Hopkins University (2) · Mateon Therapeutics (2) · Medical University of Vienna (2) · Meyer Children's Hospital IRCCS (2) · National Eye Institute (NEI) (2)
United States (57) · Italy (9) · France (8) · Australia (7) · United Kingdom (7) · China (5) · Germany (5) · Canada (4) · Israel (4) · Spain (4) · Austria (3) · Belgium (3) · Brazil (3) · Poland (3) · Czechia (2)
Reza Dana, MD, MPH, MSc (4) · Dennis M. Marcus, M.D. (2) · Gabriela Burian, MD (2) · Gregg T Kokame, MD, MMM (2) · Joel Naor, MD (2) · Luca Filippi, MD (2) · Adam Turpcu, PhD (1) · Adrienne Scott, Doctor (1) · Ahmad M Mansour, MD (1) · Alireza Ramezani, MD (1)
PMID 11071039, PMID 11741106, PMID 12707595, PMID 14557174, PMID 16765697, PMID 16897221, PMID 19376495, PMID 19549103, PMID 19726427, PMID 19936307, PMID 20136420, PMID 20375343, PMID 20609706, PMID 20847709, PMID 21704964, PMID 22424834, PMID 22426346, PMID 22707516, PMID 22990319, PMID 23233252, PMID 23316779, PMID 23352196, PMID 24001532, PMID 24604308, PMID 25079064, PMID 25376617, PMID 25646029, PMID 25677668, PMID 26114826, PMID 26431823, PMID 27020759, PMID 27030277, PMID 27124775, PMID 27814346, PMID 27865764, PMID 28614154, PMID 28709412, PMID 30098917, PMID 30957581, PMID 31134171, PMID 31956432, PMID 32729888, PMID 32729897, PMID 34201045, PMID 37422192, PMID 37816266, PMID 37868796, PMID 38979716, PMID 39207600, PMID 40038272
2009 (2), 2014 (1)